Globally, there are 9,052 marketed products for ENT disorders. Most of these pharmaceuticals are small molecules and generics that target G protein-coupled receptors (GPCRs), nuclear receptors, and microbial membranes.
30 January 2019 Comment
12 February 2018 Comment
GlaxoSmithKline (GSK) is expected to have two of the top-five best-selling drugs in the respiratory market in 2018, maintaining its strong portfolio of products in this market.
20 August 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA)...
18 April 2016
GlaxoSmithKline (GSK) has expanded its respiratory medicines production capacity with the opening of a new £56m manufacturing facility in Ware, UK.
3 April 2016
Sandoz Canada has expanded its product range with the introduction of a new respiratory antibiotic, Tobramycin inhalation solution.
16 December 2015
AstraZeneca has entered two agreements in Japan and China as part of its aim to strengthen its operations in these regions to meet growing sales.
3 March 2015
AstraZeneca has completed the acquisition of Actavis's branded respiratory business in the US and Canada for around $600m.
5 February 2015
AstraZeneca has signed an agreement with Actavis to acquire its branded respiratory business in the US and Canada, for an initial consideration of around $600m.
22 September 2014
Researchers from the University College London have discovered a new gene associated to a rare disease, which induces respiratory problems similar to cystic fibrosis.